Magnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback